ADC2122 / ZovaBio, Adcoris, Zhejiang Hisun - LARVOL DELTA

ZV0203-001CN: Study of ZV0203 in Patients with HER2-Positive Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=36 | Enrolling by invitation | Sponsor: Hangzhou Adcoris Biopharmacy Co., Ltd | Trial completion date: Jul 2024 ➔ Jul 2025

Trial completion date • Oncology • Solid Tumor • HER-2

First-in-human phase I/IIa clinical trial of ZV0203, a novel pertuzumab-based antibody-drug conjugate (ADC), in patients (pts) with Her2 positive advanced solid tumors (ESMO 2024) - P1 | "In preclinical studies, ZV0203 outperformed Kadcyla and Enhertu across various CDX models, demonstrating notable antitumor efficacy without significant toxicity. ZV0203, the first in class pertuzumab ADC, was well tolerated and demonstrated promising antitumor activity in heavily pretreated Her2 positive pts. The results support continued development."

Clinical • Metastases • P1/2 data • Colorectal Cancer • Genito-urinary Cancer • HER2 Breast Cancer • Oncology • Prostate Cancer • Solid Tumor • HER-2

Phase 1 study of ZV0203, a first in class pertuzumab ADC, in patients with HER2 positive advanced solid tumors. (ASCO 2024) - P1 | "In preclinical studies, ZV0203 demonstrated superior antitumor activity compared to Kadcyla in multiple tumor cell line xenograft models with no noticeable toxicity. ZV0203 was well tolerated and showed clinically encouraging anti-tumor activity in heavily pretreated pts with HER2 positive cancer. Clinical trial information: NCT05423977."

Clinical • Metastases • P1 data • Anemia • Dry Eye Disease • Hematological Disorders • HER2 Breast Cancer • Leukopenia • Neutropenia • Oncology • Ophthalmology • Solid Tumor • HER-2

Phase I study of ZV0203, a first in class pertuzumab ADC, in patients with HER2+ advanced solid tumors (ESMO 2023) - P1 | "In preclinical studies, ZV0203 demonstrated superior antitumor activity compared to Kadcyla in multiple tumor cell line xenograft models with no noticeable toxicity. Conclusions ZV0203 has a manageable safety profile with preliminary antitumor activity in heavily pretreated pts with HER2+ cancer. Further evaluation at higher doses is underway."

Clinical • Metastases • P1 data • HER2 Breast Cancer • Oncology • Solid Tumor • HER-2

Development of a bridging ELISA for detection of antibodies against ZV0203 in cynomolgus monkey serum. (PubMed, J Pharmacol Toxicol Methods) - "The results showed that the method is suitable for the detection of anti-ZV0203 antibodies in cynomolgus monkey serum. The assay was also successfully applied in the repeated dose study of ZV0203."

Journal • Preclinical • Hematological Disorders

Study of ZV0203 in Patients With HER2-Positive Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=36 | Enrolling by invitation | Sponsor: Hangzhou Adcoris Biopharmacy Co., Ltd

New P1 trial • Oncology • Solid Tumor • HER-2